Healthcare Industry News:  Belcher Pharmaceuticals 

Biopharmaceuticals Generics Litigation

 News Release - October 10, 2006

GeoPharma Announces Schering-Plough Lawsuit Related to Generic Version of Clarinex(R)

LARGO, Fla., Oct. 10 (HSMN NewsFeed) -- GeoPharma, Inc. (Nasdaq: GORX ) today announced that Schering-Plough (NYSE: SGP ), has filed a lawsuit against the Company and its wholly owned subsidiary, Belcher Pharmaceuticals, Inc. in the United States District Court, District of New Jersey (No. 3:06-cv-04715-MLC-TJB), alleging patent infringement related to Belcher's filing for a generic version of Clarinex® Desloratadine 5 mg tablets. On June 21, 2006, Belcher submitted its Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration, and included a "Paragraph IV" certification under the Hatch-Waxman Act, certifying that Belcher believes its proposed generic version of Clarinex tablets do not infringe Schering's patents listed in the FDA's "Orange Book" or that the listed patents are invalid or unenforceable. The Hatch-Waxman Act provides for a 180 day period of exclusivity to one or more proposed generic manufacturers that are the first to file an ANDA with a Paragraph IV certification, and prevail in the litigation. Belcher believes that it is among the first to file, but is not able to confirm this. Belcher was one of multiple generic drug companies named as defendants in the action. According to the complaint, the other defendants are alleged to have filed their ANDA's and Paragraph IV certifications on the same day as Belcher, June 21, 2006. Schering Plough markets Clarinex ® for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria. According to Schering-Plough, U.S. sales of Clarinex for 2005 were $325 million.

About GeoPharma, Inc.

GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high-margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at , and .


This press release may contain statements that constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

L.G. Zangani, LLC provides financial public relations services to the Company. As such, L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and/or other services performed for the Company. This remuneration may take the form of cash, capital stock in the Company, or warrants and/or options to purchase stock in the Company.

Source: GeoPharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.